3,4-dihydroxyphenylacetic acid has been researched along with Alzheimer Disease in 19 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tamoxifen (TMX) is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer." | 5.43 | Memory enhancement by Tamoxifen on amyloidosis mouse model. ( Banerjee, S; Basu, M; Mishra, N; Pandey, D, 2016) |
| "Mean levels of the two hydrolases angiotensin-converting enzyme (ACE) and acetylcholinesterase (AChE), the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and total protein concentration were examined in cerebrospinal fluid (CSF) samples from a group of patients with dementia of the Alzheimer's type, a group of comparably demented patients with Parkinson's disease, and a neurologically healthy elderly control group." | 3.67 | Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. ( Direnfeld, LK; Langlais, PJ; Marquis, JK; Nixon, RA; Volicer, L; Zubenko, GS, 1986) |
| "Tamoxifen (TMX) is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer." | 1.43 | Memory enhancement by Tamoxifen on amyloidosis mouse model. ( Banerjee, S; Basu, M; Mishra, N; Pandey, D, 2016) |
| "Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are present during the disease course of nearly all AD patients and consist of psychosis, agitation/aggression, and depression, among others." | 1.40 | Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. ( Aerts, T; De Deyn, PP; Engelborghs, S; Van Dam, D; Vermeiren, Y, 2014) |
| "Furthermore, 6 of 15 untreated Parkinson's disease patients (40%) displayed markedly elevated plasma concentrations of the catecholamine MAO metabolites, DOPAC or DOPEG." | 1.29 | Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. ( Ahlskog, JE; Kokmen, E; O'Brien, JF; Petersen, RC; Tyce, GM; Uitti, RJ, 1996) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Laranjinha, J | 1 |
| Nunes, C | 1 |
| Ledo, A | 1 |
| Lourenço, C | 1 |
| Rocha, B | 1 |
| Barbosa, RM | 1 |
| Abdel-Hafiz, L | 1 |
| Müller-Schiffmann, A | 1 |
| Korth, C | 1 |
| Fazari, B | 1 |
| Chao, OY | 1 |
| Nikolaus, S | 1 |
| Schäble, S | 1 |
| Herring, A | 1 |
| Keyvani, K | 1 |
| Lamounier-Zepter, V | 1 |
| Huston, JP | 1 |
| de Souza Silva, MA | 1 |
| Vermeiren, Y | 1 |
| Van Dam, D | 1 |
| Aerts, T | 1 |
| Engelborghs, S | 1 |
| De Deyn, PP | 1 |
| Pandey, D | 1 |
| Banerjee, S | 1 |
| Basu, M | 1 |
| Mishra, N | 1 |
| Esteban, G | 1 |
| Van Schoors, J | 1 |
| Sun, P | 1 |
| Van Eeckhaut, A | 1 |
| Marco-Contelles, J | 1 |
| Smolders, I | 1 |
| Unzeta, M | 1 |
| Minematsu, M | 1 |
| Nakajima, K | 1 |
| Sasaki, M | 1 |
| Sanada, H | 1 |
| Mena, MA | 1 |
| Aguado, EG | 1 |
| de Yebenes, JG | 1 |
| Langlais, PJ | 3 |
| Thal, L | 1 |
| Hansen, L | 1 |
| Galasko, D | 1 |
| Alford, M | 1 |
| Masliah, E | 1 |
| Bierer, LM | 1 |
| Knott, PJ | 1 |
| Schmeidler, JM | 1 |
| Marin, DB | 1 |
| Ryan, TM | 1 |
| Haroutunian, V | 1 |
| Purohit, DP | 1 |
| Perl, DP | 1 |
| Mohs, RC | 1 |
| Davis, KL | 1 |
| Storga, D | 1 |
| Vrecko, K | 1 |
| Birkmayer, JG | 1 |
| Reibnegger, G | 1 |
| Ahlskog, JE | 1 |
| Uitti, RJ | 1 |
| Tyce, GM | 1 |
| O'Brien, JF | 1 |
| Petersen, RC | 1 |
| Kokmen, E | 1 |
| Tatton, WG | 1 |
| Wadia, JS | 1 |
| Ju, WY | 1 |
| Chalmers-Redman, RM | 1 |
| Tatton, NA | 1 |
| Hoogendijk, WJ | 1 |
| Feenstra, MG | 1 |
| Botterblom, MH | 1 |
| Gilhuis, J | 1 |
| Sommer, IE | 1 |
| Kamphorst, W | 1 |
| Eikelenboom, P | 1 |
| Swaab, DF | 1 |
| Liu, HC | 1 |
| Yang, JC | 1 |
| Chang, YF | 1 |
| Liu, TY | 1 |
| Chi, CW | 1 |
| Palmer, AM | 1 |
| Wilcock, GK | 1 |
| Esiri, MM | 1 |
| Francis, PT | 1 |
| Bowen, DM | 1 |
| Koyama, E | 1 |
| Minegishi, A | 1 |
| Ishizaki, T | 1 |
| Volicer, L | 2 |
| Direnfeld, LK | 2 |
| Freedman, M | 1 |
| Bird, ED | 1 |
| Albert, ML | 1 |
| Zubenko, GS | 1 |
| Marquis, JK | 1 |
| Nixon, RA | 1 |
3 reviews available for 3,4-dihydroxyphenylacetic acid and Alzheimer Disease
| Article | Year |
|---|---|
The Peculiar Facets of Nitric Oxide as a Cellular Messenger: From Disease-Associated Signaling to the Regulation of Brain Bioenergetics and Neurovascular Coupling.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Brain; Energy Metabolism; Humans; Mitoch | 2021 |
[3,4-Dihydroxyphenylacetic acid (DOPAC)].
Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Alzheimer Disease; Biomark | 2005 |
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Express | 1996 |
16 other studies available for 3,4-dihydroxyphenylacetic acid and Alzheimer Disease
| Article | Year |
|---|---|
Aβ dimers induce behavioral and neurochemical deficits of relevance to early Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Be | 2018 |
Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Biogenic Monoam | 2014 |
Memory enhancement by Tamoxifen on amyloidosis mouse model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Animals; Corp | 2016 |
In-vitro and in-vivo evaluation of the modulatory effects of the multitarget compound ASS234 on the monoaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Biogenic Monoamines; Cell Line, Tumor; D | 2017 |
Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Alzheimer Disea | 2008 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Basal Ganglia; Brain; Brain Chemistry; Caudate Nu | 1993 |
Post-mortem examination of dopaminergic parameters in Alzheimer's disease: relationship to noncognitive symptoms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Alzheimer Disease; Dopamine; Female; Homova | 1993 |
Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Alzheimer Disease; Brain; Dopamine; Epinephrine; Humans; Middl | 1996 |
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Catecho | 1996 |
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Amygdala; Cell Count; Cell Survival; Dopamine; Fe | 1999 |
Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; China; Chromatography, High Pressure Liquid; Dihy | 1991 |
Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Biogenic Amines; | 1987 |
Simultaneous determination of four monoamine metabolites and serotonin in cerebrospinal fluid by "high-performance" liquid chromatography with electrochemical detection; application for patients with Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Electrochem | 1988 |
Catecholamine metabolites and cyclic nucleotides in cerebrospinal fluid in dementia of Alzheimer type.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Alzheimer Disease; Catecholamines; Cyclic AMP; Cyclic GMP; Hom | 1985 |
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; Aged; Alzheimer Disease; Cerebrospinal Fluid P | 1986 |